Amarin ហៅ Activist Investor ដែលជាម្ចាស់ភាគហ៊ុនធំជាងគេ សេចក្តីថ្លែងការណ៍របស់ Sarisa 'មិនត្រឹមត្រូវ, បំភាន់'

• Amarin Corporation Plc (ផ្សារហ៊ុន NASDAQ: អេអឹមអិន) reacted to its largest shareholder, Sarissa Capital Management, which said Amarin’s recent board refreshment put “no shareholder representatives on the board.”

• Sarissa said in its statement Wednesday that Amarin “has repeatedly overpromised and underdelivered,” with the European launch being delayed and reimbursement in Germany appearing to be imperiled.

• Amarin described Sarissa’s published statement as “inaccurate and misleading.”

• The drugmaker said its board refreshment process was “comprehensive, independent and transparent,” and Sarissa’s candidates “are not qualified” compared with recently appointed board members.

• Amarin says the board refreshment process has been comprehensive, independent, and transparent.

• The company also says Sarissa’s intervention will lead to distraction, disruption, and destruction of future value.

• Earlier this month, for Q4 and FY22, Amarin forecasted revenues of $88-$90 million and $367-$369 million, respectively, reflecting ongoing stabilization of the U.S. business for Vascepa (icosapent ethyl).

• Amarin ended 2022 with approximately $310 million in cash and investments, with a positive cash flow of approximately $4 million in the fourth quarter of 2022.

• សកម្មភាពតម្លៃ: AMRN shares are flat at $1.85 on the last check Thursday.

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។